Neovasc (NASDAQ:NVNC) reported positive long term safety and efficacy data for its Reducer device in 50 patients suffering from refractory disabling angina.
Neovasc’s Reducer relives angina symptoms by altering blood flow in the heart, which increases delivery of oxygenated blood to ischemic areas. The Reducer is inserted using a minimally-invasive transvenous procedure similar to the one used to implant a coronary stent.
“This study shows us that the Reducer has a sustained therapeutic effect at two years across a large patient population,” Prof. Shmuel Banai, Neovasc’s medical director, said in a statement.
“In addition, we believe this study provides valuable long-term safety data that further supports cardiologists’ use of the Reducer as a therapeutic option for patients suffering from refractory angina,” he added.
The Reducer is not approved for commercial use in the U.S., however Neovasc obtained FDA breakthrough designation for the device in October 2018. The Reducer is CE-marked in the EU.
The findings have been published in the peer-reviewed International Journal of Cardiology. The article can be accessed here.
